Northwire Canada EditionTuesday, July 14, 2026
Sign inSubscribe
Northwire
⌕
WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8% WDO 26.04 −0.9% FVI 11.84 −1.6% OM 1.75 −1.7% ETG 2.99 +0.0% ARTG 31.47 −4.6% LUC 0.163 +1.6% AFM 1.38 +0.0% IMG 20.95 −3.5% CPAU 0.150 +3.5% MMX 0.075 +7.1% IE 12.47 −2.4% SASK 1.09 −1.8% MOG 0.390 +2.6% XIM 0.070 −6.7% S 0.110 −29.0% OMI 0.300 −4.8%

Healthcare

Page 49
  1. Mar 12, 2026 · 07:00 · DR

    Medical Facilities Corporation Reports Fourth Quarter and FY 2025 Results

    Medical Facilities Corporation Reports Fourth Quarter and FY 2025 Results

    01
  2. Mar 12, 2026 · 06:30 · HLS

    HLS Therapeutics Announces Fiscal 2025 Financial Results

    HLS Therapeutics Announces Fiscal 2025 Financial Results

    02
  3. Mar 11, 2026 · 22:58 · NVRS

    Noveris Announces Life Offering

    Noveris Announces Life Offering

    03
  4. Mar 11, 2026 · 19:55 · QNTM

    Quantum BioPharma Provides Corporate Update

    Quantum BioPharma Provides Corporate Update

    04
  5. Mar 11, 2026 · 19:53 · NRX

    Nurexone signs consulting agreement, closes financing

    Nurexone signs consulting agreement, closes financing

    05
  6. Mar 11, 2026 · 18:42 · INNO

    Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest

    Innocan Pharma Announces Offering of a Debenture to its Largest Shareholder, Tamar Innovest

    06
  7. Mar 11, 2026 · 17:34 · RVV

    Revive Therapeutics advances bucillamine patents

    Revive Therapeutics advances bucillamine patents

    07
  8. Mar 11, 2026 · 17:15 · VIVI

    Tempramed's Vivi Cap evaluated for summer travel use

    Tempramed's Vivi Cap evaluated for summer travel use

    08
  9. Mar 11, 2026 · 16:17 · AIAI

    Netramark signs contract for client's depression trial

    Netramark signs contract for client's depression trial

    09
  10. Mar 11, 2026 · 08:28 · NRX

    NurExone Announces Corporate Updates

    NurExone Announces Corporate Updates

    10
  11. Mar 11, 2026 · 07:30 · RVV

    Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

    Revive Therapeutics Strengthens Bucillamine IP Portfolio with North American Patent Filings for Nerve Agent Exposure and Granted Canadian Patent for Infectious Diseases

    11
  12. Mar 11, 2026 · 07:01 · VIVI

    TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

    TempraMed's Independently Validated Payer ROI Model for Reimbursement Further Reinforced by a Scientific Publication Highlighting Clinical and Economic Rationale for VIVI Cap

    12
  13. Mar 11, 2026 · 07:00 · AIAI

    NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

    NetraMark Signs Contract With Global Biopharmaceutical Company to Analyze Phase 2 Depression Trial Data

    13
  14. Mar 10, 2026 · 19:45 · QNTM

    Quantum BioPharma Provides Corporate Update

    Quantum BioPharma Provides Corporate Update

    14
← Newer Older →